Have you ever wondered why so much health data goes unused? It's mainly because of privacy issues and rules around data protection. This is where Apheris comes in. Founded by German entrepreneur Robin Röhm, this startup is tackling the problem of using AI in life science and pharmaceuticals.

You see, AI needs data to work. But so often, important health data can't be used because of privacy concerns and regulations. This is what Apheris is trying to change with its federated computing method.

Instead of moving data to where the AI models are, Apheris does the opposite. It keeps the data where it is and only sends the results of calculations to a central hub. This means sensitive data stays secure.

Roche and several hospitals are already using Apheris. The startup has just raised $8. 25 million in a Series A funding round, led by deep tech investors OTB Ventures and eCAPITAL.

Apheris has shifted its focus to work with data owners, especially in the pharma and life science fields. They found that their new approach really worked. Since their change in direction, their revenue has quadrupled.

With this new funding, Apheris plans to hire more experts in life science. They'll also focus on new areas like protein complex prediction. This is a topic where public data is scarce, but valuable private data is abundant.

Apheris believes that by addressing data owners' concerns, AI's full potential can be unleashed. And that's the core mission of their work.

Unlocking Life Science AI: How Apheris Keeps Data Safe and Secure

Actions